A S A S Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: A S A S Pharmaceutical Import Records from India — 2 Products, $180.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

A S A S — Pharmaceutical Importer Profile (2026) | 2 Products, $180.4K Trade | TransData Nexus

A S A S

Pharmaceutical Importer · Colombia · Advanced Oncology Focus · $180.4K Total Trade · DGFT Verified

A S A S is a pharmaceutical importer based in Colombia with a total trade value of $180.4K across 2 products in 2 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. A S A S sources from 16 verified Indian suppliers, with Venus Remedies Limited accounting for 46.1% of imports.

A S A S — Import Portfolio & Supplier Network

A S A S import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to A S A S?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Venus Remedies Limited	$1.5M	83	46.1%
Naprod Life Sciences Private Limited	$471.6K	23	14.6%
Aurobindo Pharma Limited	$365.0K

What Formulations Does A S A S Import?

Formulation	Value	Ships
Oxaliseven 100 oxaliplatin for	$178.6K	6
Sertraline 50MG tablets (aurasert 50) 2x14	$100.0K	2
Abacavir sulfate and lamivudine tablets600/300MG (abacavir 600 MG y lamivudina300 MG tabletas) 30	$100.0K	2
11408 human immunoglobulin 5 100ML vial	$100.0K	2
Oxaliseven 100 oxaliplatin for injection USP 100MG	$89.3K	3
Yutaxan paclitaxel injectable	$82.8K	3
Doxorubicin hydrochloride solution for injection 50MG/25ML doxorubicin 50 MG bn.x4cdx022a,x4cdx032a md.3/2024	$56.4K	3
Levosimendan injection 2.5 MG/ML bno.	$56.0K	2
Capecitabine tablets 500MG (pacsita	$50.0K	1
Human normal immunoglobulin 5 100 ML	$50.0K	1
Adsorbed tetanus vaccine BP single dosevail 0 5 ML as per	$50.0K	1
Hepatitis b vaccine rdna BP adult dose 1ML vial as per	$50.0K	1
Pharmaceuticals products fenoblasius fenofibrate sustained release capsules 250MG Pack 10	$50.0K	1
Pharma bicnu 100 MG injection carmustine for injection 100 MG 1 vial invoice no 2211100297 dt 15 11	$50.0K	1
Cisplatin injection BP 50 MG/100 ML e.	$50.0K	1

A S A S imports 131 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bleomycin	Advanced Oncology	$96.5K	5	1.7%	9
2	Vincristine	Oncology	$83.9K	6	2.9%	5

A S A S imports 2 pharmaceutical products across 2 categories into Colombia totaling $180.4K.

A S A S — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

A S A S is a pharmaceutical importer and buyer based in Colombia, specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company plays a pivotal role in the Colombian pharmaceutical distribution network by sourcing and importing a range of pharmaceutical products to meet the domestic market's needs. While specific details about its headquarters, parent company, and organizational structure are not publicly available, A S A S's operations are integral to the supply chain, ensuring the availability of essential medications within Colombia.

2Distribution Network

Information regarding A S A S's warehouse locations, logistics capabilities, and geographic coverage within Colombia is not publicly disclosed. However, given the company's focus on importing pharmaceutical products, it is likely that A S A S collaborates with established logistics providers to facilitate the efficient distribution of its products across the country. The company's reliance on international suppliers, particularly from India, suggests a well-coordinated logistics network to manage the importation and distribution processes effectively.

3Industry Role

A S A S operates as a pharmaceutical importer and buyer within Colombia's pharmaceutical supply chain. Its primary function is to source and import finished pharmaceutical formulations from international suppliers, with a significant emphasis on products from India. By doing so, A S A S contributes to the diversification and availability of pharmaceutical products in the Colombian market, catering to various therapeutic needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — A S A S

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

A S A S's sourcing strategy exhibits a high degree of concentration, with a portfolio entirely composed of two products: Bleomycin and Vincristine. This singular focus on oncology medications indicates a strategic choice to specialize in a niche market segment, potentially allowing the company to develop expertise and strong relationships within this therapeutic area. The substantial import values—$96K for Bleomycin and $84K for Vincristine—reflect a stable demand and a consistent supply chain for these products. However, this concentration also poses risks; any disruptions in the supply chain, such as regulatory changes or supplier issues, could significantly impact A S A S's operations. The company's reliance on a limited number of products suggests a need for strategic planning to mitigate potential risks associated with such concentration.

2Supply Chain Resilience

A S A S's supply chain resilience is closely tied to its sourcing strategy, which is heavily dependent on a select group of Indian suppliers. The company's top suppliers include Venus Remedies Limited, Naprod Life Sciences Private Limited, and Aurobindo Pharma Limited, collectively accounting for a significant portion of the total import value. This concentrated supplier base may enhance operational efficiency and foster strong supplier relationships. However, it also exposes A S A S to potential risks, such as supply disruptions or changes in supplier policies. The company's focus on a limited number of formulations—131 unique formulations—indicates a streamlined product offering, which could be advantageous in terms of inventory management and regulatory compliance. To bolster supply chain resilience, A S A S may consider diversifying its supplier base and product portfolio, thereby reducing dependency on a narrow segment and enhancing its ability to adapt to market changes.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the primary regulatory authority overseeing pharmaceutical products is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Colombian market. The regulatory framework governing pharmaceutical imports includes Decree 677 of 1995, which outlines the sanitary registration requirements for drugs and biological products. This decree mandates that all pharmaceutical products imported into Colombia must undergo a registration process with INVIMA, ensuring they meet the necessary standards for public health. Additionally, Decree 1165 of 2019, as amended by Decree 360 of 2021, provides comprehensive guidelines on the importation of pharmaceutical products, detailing procedures for customs clearance, documentation, and compliance with health regulations. These regulations are designed to protect public health by ensuring that all pharmaceutical products entering Colombia are safe for consumption and effective in their intended use.

2Import Licensing & GMP

Importers of pharmaceutical products into Colombia must adhere to specific licensing requirements. They are required to register with the National Tax and Customs Directorate (DIAN) and obtain a Tax Identification Number (NIT). Additionally, importers must be registered in the Single Tax Registry (RUT) and have access to the Single Window for Foreign Trade (VUCE) platform. For products subject to special controls, such as controlled substances, importers must obtain prior approval from the Ministry of Commerce, Industry and Tourism (MinCIT) for the Import Registration Form or Import License. Furthermore, when applicable, importers must secure permits from pertinent government agencies, such as INVIMA for health-related products, before the cargo departs from the country of origin. Regarding Good Manufacturing Practice (GMP) certification, Colombia recognizes certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized organizations to comply with Colombian regulations. Additionally, importers must obtain wholesale distribution authorization from INVIMA, which involves demonstrating compliance with storage, handling, and distribution standards to ensure the integrity of pharmaceutical products throughout the supply chain.

A S A S — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

A S A S's product strategy focuses exclusively on oncology medications, importing finished pharmaceutical formulations such as Bleomycin and Vincristine. This strategic focus aligns with the company's specialization in the oncology therapeutic area, catering to the specific needs of patients requiring cancer treatments. The decision to concentrate on these products may be driven by factors such as market demand, the company's expertise in oncology, and the potential for establishing strong supplier relationships within this niche segment. By focusing on a limited number of products, A S A S can streamline its operations, maintain a high level of product knowledge, and ensure the quality and efficacy of the medications it imports.

2Sourcing Profile

A S A S's sourcing strategy is characterized by a concentrated approach, importing finished pharmaceutical formulations exclusively from India. The company's top suppliers include Venus Remedies Limited, Naprod Life Sciences Private Limited, and Aurobindo Pharma Limited, indicating a preference for established Indian pharmaceutical manufacturers. This sourcing profile suggests a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities, particularly in the oncology sector, to meet the specific needs of the Colombian market. By focusing on a select group of suppliers, A S A S can develop strong partnerships, ensure consistent product quality, and potentially negotiate favorable terms.

Frequently Asked Questions — A S A S

What products does A S A S import from India?

A S A S imports 2 pharmaceutical products across 2 categories. Top imports: Bleomycin ($96.5K), Vincristine ($83.9K).

Who supplies pharmaceuticals to A S A S from India?

A S A S sources from 16 verified Indian suppliers. The primary supplier is Venus Remedies Limited (46.1% of imports, $1.5M).

What is A S A S's total pharmaceutical import value?

A S A S's total pharmaceutical import value from India is $180.4K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does A S A S focus on?

A S A S imports across 2 categories. The largest: Advanced Oncology (53.5%), Oncology (46.5%).

Get Full A S A S Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

A S A S

A S A S — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to A S A S?

What Formulations Does A S A S Import?

What Products Does A S A S Import?

Top Products by Import Value

A S A S Therapeutic Categories — 2 Specializations